RayzeBio, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYZB research report →
Price Chart
About the company
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- CEO
- Kenneth Song
- IPO
- 2023
- Employees
- 88
- HQ
- DE, US
Get TickerSpark's AI analysis on RYZB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.75B
- P/E
- -35.71
- PEG
- -0.36
- P/S
- 0.00
- P/B
- -22.02
- EV/EBITDA
- -54.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 82.72%
- ROIC
- -22.86%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-72,120,000
- Net Income
- $-68,600,000-133.0%
- EPS
- $-1.75-139.7%
- OCF Growth
- -66.0%
- FCF Growth
- -65.5%
- 52W High
- $62.51
- 52W Low
- $17.95
- 50D MA
- $55.78
- 200D MA
- $36.72
- Beta
- 3.79
- RSI (14)
- 88
- Avg Volume
- 745.49K
No earnings-call transcripts are available for RYZB yet.
- Free Float
- 58.0%
- Shares Outstanding
- 60.02M
- Float Shares
- 34.82M
of shares held by institutions
68 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Weiss Multi-Strategy Advisers LLC | 23.41K | ▲ 23.41K |
| Kellner Capital, LLC | 12.20K | ▲ 12.20K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 24 | VIKING GLOBAL INVESTORS LP | other | 1,743,556 |
| Sep 19, 23 | Redmile Group, LLC | other | 498,510 |
| Sep 19, 23 | Redmile Group, LLC | other | 494,687 |
| Sep 19, 23 | Redmile Group, LLC | other | 864,509 |
| Sep 19, 23 | Redmile Group, LLC | other | 498,510 |
| Sep 19, 23 | Redmile Group, LLC | other | 864,509 |
| Sep 19, 23 | Redmile Group, LLC | other | 432,254 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 247,343 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 1,123,862 |
| Sep 19, 23 | venBio Global Strategic Fund III, L.P. | other | 3,786,957 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RYZB coverage
Recent articles, reports, and earnings notes.
No research on RYZB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RYZB report →Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
businesswire.com · Feb 26
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
businesswire.com · Feb 23
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
businesswire.com · Feb 12
IPO watch 2024: Which new stocks will hit the market?
marketbeat.com · Jan 8
Cramer names biopharma companies to watch as industry mergers start to pile up
cnbc.com · Jan 5
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
businesswire.com · Dec 31
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
marketwatch.com · Dec 27
Yes Virginia, There Is a Santa Claus Rally
zacks.com · Dec 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.